Figure 5

Doxorubicin and phleomycin stimulation of ssODN-, dsDNA-, and rAAV-mediated episomal gene repair. (A) HEK293T cells were treated with increasing doses of doxorubicin 24 h prior to transfection with the pmeGFP plasmid and either the GFP PO AS Rep oligonucleotide (molar ratio 1/100, grey bars), the GFP dsDNA 700 fragment (molar ratio 1/10, white bars) or with the rAAV-GFPLuc vector (black bars). (B) HEK293T cells were exposed to various doses of phleomycin 24 h prior to transfection with the pmeGFP plasmid and either the GFP PO AS Rep oligonucleotide (molar ratio 1/100, grey bars), the GFP dsDNA 700 fragment (molar ratio 1/10, white bars) or with the rAAV-GFPLuc vector (black bars). (C) Cell cycle distribution of non-treated (left), doxorubicin-treated (middle) and phleomycin-treated cells (right).